Comparison of Late Toxicity After Whole-pelvis Versus Prostate-only VMAT for Prostate Cancer
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND/AIM: To evaluate whether whole-pelvis (WP) volumetric modulated arc therapy (VMAT) is associated with increased late toxicity compared with prostate-only (PO) VMAT in patients with localized prostate cancer. PATIENTS AND METHODS: Participants comprised 384 consecutive patients treated with definitive VMAT to 78 Gy in 39 fractions from July 2011 to August 2016. Of these, 183 patients received PO-VMAT and 201 patients received initial WP-VMAT to 46.8 Gy in 26 fractions using a simultaneous integrated boost technique. Gastrointestinal (GI) and genitourinary (GU) toxicities were prospectively scored using Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Median follow-up was 49 months (range=16-88 months) in the PO-VMAT group and 52 months (range=10-85 months) in the WP-VMAT group. Frequencies of Grade 3 late GI and GU toxicities were ≤3% across both groups. No patients experienced Grade 4+ toxicity. Cumulative incidences of Grade 2+ late GI and GU toxicities were similar between PO- and WP-VMAT groups (p=0.508 and p=0.838, respectively). Five-year cumulative incidences of Grade 2+ late GI and GU toxicities were 12.2% and 6.6% for the PO-VMAT group and 12.3% and 8.9% for the WP-VMAT group, respectively. CONCLUSION: WP-VMAT did not increase late GI and GU toxicities. This suggests that concerns about increasing toxicity profile are insufficient reason for omitting WPRT for patients with high-risk prostate cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparison of Late Toxicity After Whole-pelvis Versus Prostate-only VMAT for Prostate Cancer
- Date Crossref
- 03/11/2022
- Éditeur
- International Institute of Anticancer Research
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Osaka Minami Medical Center Department of Radiology pays non établi dans la noticeÉtablissement de santé
-
Tane General Hospital Department of Radiation Oncology pays non établi dans la noticeÉtablissement de santé
-
Kindai University pays non établi dans la noticeUniversité ou école supérieure
-
Osaka City University pays non établi dans la noticeUniversité ou école supérieure
-
Tokyo Metropolitan University pays non établi dans la noticeUniversité ou école supérieure
-
Izumi City General Hospital Department of Radiology pays non établi dans la noticeÉtablissement de santé
-
Graduate School of Medical Sciences Department of Medical Physics pays non établi dans la noticeUniversité ou école supérieure
-
Osaka Metropolitan University Graduate School of Medicine Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
Department of Radiology — Osaka Minami Medical Center, Department of Radiation Oncology — Tane General Hospital et Kindai University, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.